Summit Therapeutics revenue and financials
$17.31Change from previous close: +0.23%Absolute change: +$0.04
Fiscal year ending in December. Sources and method on the page Methodology and sources.
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | FY to Jan 2019 | FY to Jan 2018 | FY to Jan 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 751 | 436 | 203 | 664 | 113 | 102 | 96.2 | 60.6 | 55.2 | 37.6 |
| Current assets | 720 | 424 | 190 | 657 | 97.3 | 87.7 | 60.2 | 46.7 | 35.8 | 33.3 |
| Cash and equivalents | 225 | 105 | 71.4 | 349 | 71.8 | 66.4 | 48.4 | 35.2 | 28.5 | 28.1 |
| Short-term investments | 488 | 307 | 115 | 0.0 | — | — | — | — | — | — |
| Receivables | — | 0.6 | 0.8 | 6.1 | 17.2 | — | — | — | — | — |
| Net property, plant and equipment | 21.7 | 7.4 | 6.1 | 5.1 | 3.5 | — | — | — | — | — |
| Goodwill | 2.0 | 1.9 | 1.9 | 1.8 | 2.0 | 2.0 | 2.0 | 2.0 | 2.5 | 0.7 |
| Other intangible assets | — | — | — | — | 10.4 | — | — | — | — | — |
| Current liabilities | 73.0 | 41.7 | 20.4 | 38.8 | 25.6 | 19.9 | 9.6 | 13.1 | 23.0 | 10.9 |
| Accounts payable | 20.3 | 4.6 | 2.7 | 0.4 | 4.4 | — | — | — | — | — |
| Long-term debt | — | — | 100 | 495 | — | — | — | — | — | — |
| Total debt | 20.9 | 7.2 | 106 | 519 | — | — | — | — | — | — |
| Total liabilities | 92.3 | 46.8 | 125 | 538 | 30.1 | 23.0 | 17.4 | 18.1 | 58.3 | 41.1 |
| Total equity (incl. minority) | 659 | 389 | 77.7 | 127 | 83.3 | — | — | — | — | — |
| Retained earnings | -2,294 | -1,215 | -993 | -378 | -300 | — | — | — | — | — |